Long-Term Use of Lilly's Taltz(R) (ixekizumab) Shows Efficacy Improvements in Psoriatic Arthritis for Patients with Prior Inadequate Response or Intolerance to TNF Inhibitors
Taltz also demonstrated improvements in key secondary measures, including skin clearance, at 52 weeks
INDIANAPOLIS, Nov. 8, 2017 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (NYSE: LLY) announced today patients with active psoria... Biopharmaceuticals Eli Lilly, Taltz, ixekizumab, Psoriatic Arthritis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news